Ethambutol-Associated Ocular Toxicity in Young Children

Clinical Presentation and Diagnosis

A 5-month-old infant with prolonged fever, irritability, and cough may have disseminated/miliary tuberculosis, suggested by a "snowflakes appearance" on chest X-ray and no BCG vaccination, increasing susceptibility to disseminated disease 1
The American Thoracic Society suggests that prolonged fever and irritability in infants can be indicative of meningeal involvement in tuberculosis 1

Ethambutol causes retrobulbar neuritis (optic neuritis), manifesting as decreased visual acuity, scotomata, color blindness, and visual field defects, with a dose-dependent toxicity that can be irreversible if not recognized promptly 2, 3
The American College of Chest Physicians recommends careful monitoring of visual acuity in patients taking ethambutol, as the toxicity can result in permanent blindness 3, 4

Young age (<5 years) makes visual monitoring extremely difficult, as the child cannot report visual symptoms, and visual impairment in young children is likely underestimated 3, 4
The British Thoracic Society states that ethambutol should only be used in patients who can appreciate and report visual symptoms, highlighting the risk in young children 1

The British Thoracic Society recommends baseline visual acuity testing by Snellen chart before prescribing ethambutol, and monthly monitoring for visual disturbances, including blurred vision and scotomata 1, 3
The American Academy of Pediatrics suggests that ethambutol can be used in young children when drug resistance is suspected, but with extreme caution due to the inability to monitor visual acuity 4

The FDA recommends careful calculation of the ethambutol dose at 15-20 mg/kg/day (never exceeding this) and arrangement of VEP monitoring if available, when using ethambutol in young children due to suspected drug resistance 4
The World Health Organization suggests that visual-evoked potentials (VEPs) can be used for monitoring in children too young to cooperate with standard vision testing, but this requires specialized equipment and expertise 4

The American College of Chest Physicians recommends monthly color vision testing throughout treatment, with baseline and ongoing monitoring using visual-evoked potentials (VEPs) when available, as standard visual acuity testing is not feasible in this age group, with a dosing requirement to never exceed 15-20 mg/kg/day in infants, and at the recommended 15 mg/kg/day dose, ocular toxicity in children is extremely rare (0.05% or 2 out of 3,811 children) 5
The American Journal of Respiratory and Critical Care Medicine guidelines suggest that standard Snellen chart testing and Ishihara color plates cannot be performed in infants who cannot cooperate (typically under 5 years of age), and monthly color vision testing should be performed throughout the entire duration of ethambutol therapy, with careful dose calculation essential as toxicity is dose-dependent 5

The American College of Chest Physicians guidelines recommend a parental questionnaire about any behavioral changes suggesting vision problems, color vision testing (documented monthly per guidelines), and clinical assessment for signs of visual disturbance, with VEP testing if available at months 1, 2, 4, and 6, and careful parental education about observing for behavioral changes suggesting visual impairment 5